Menu
Fluoropyrimidines are widely used for the treatment of various solid tumors. The newly launched PGX-5FU XL StripAssay® covers the four most clinically important variants with therapeutic relevance for fluoropyrimidine treatment as recommended by the European Medicines Agency in April 2020.
Click here for more information.
Mutations in the epidermal growth factor receptor (EGFR) gene are predictive of the response to EGFR tyrosine kinase inhibitors (TKIs). The assays identify 30 EGFR mutations relevant for non-small cell lung cancer (NSCLC) TKI therapy. The EGFR XL StripAssay is an assay for the identification of 30 EGFR mutations in exons 18/19/20/21 based on polymerase chain reaction (PCR) and reverse-hybridization.
Germline polymorphisms in the Fc gamma receptor (FCGR) gene have been reported to influence antibody-based cancer therapies. The FCGR StripAssay® identifies the variants FCGR2A-H131R and FCGR3A-F158V. An assay for the analysis of Fc gamma receptor (FCGR) polymorphisms based on polymerase chain reaction (PCR) and reverse-hybridization.
Monoclonal antibody (mAb) therapies targeting epidermal growth factor receptor (EGFR) are used in metastatic colorectal cancer (mCRC) therapies. KRAS StripAssays® identifies the most relevant genetic variants of KRAS genes interfering with treatment/therapy success. An assay for the identification of 10 KRAS mutations in codons 12 and 13 based on polymerase chain reaction (PCR) and reverse-hybridization.
The KRAS-BRAF StripAssay is an assay for the identification of KRAS and BRAF gene mutations based on polymerase chain reaction (PCR) and reverse-hybridization. It has ultra-sensitive detection of 10 KRAS mutations in codons 12/13 and the BRAF V600E mutation.
Monoclonal antibody (mAb) therapies targeting epidermal growth factor receptor (EGFR) are used in metastatic colorectal cancer (mCRC) therapies. KRAS XL StripAssay® identifies the most relevant genetic variants of KRAS genes interfering with treatment/therapy success. An assay for the identification of 29 KRAS mutations in codons 12/13/59/60/ 61/117/146 based on polymerase chain reaction (PCR) and reverse-hybridization.
Monoclonal antibody (mAb) therapies targeting epidermal growth factor receptor (EGFR) are used in metastatic colorectal cancer (mCRC) therapies. NRAS StripAssays® identifies the most relevant genetic variants of NRAS genes interfering with treatment/therapy success. An assay for the identification of 22 NRAS mutations in codons 12/13/59/60/ 61/146 based on polymerase chain reaction (PCR) and reverse-hybridization.
Determination of BRAF V600 mutational status is recommended in metastatic colorectal cancer (mCRC) at the same time as RAS mutational status for prognostic assessment (and/or potential selection for clinical trials). BRAF 600/601 StripAssay is an assay for the identification of 9 BRAF mutations in codons 600 and 601 based on polymerase chain reaction (PCR) and reverse-hybridization.
BRAF gene mutation assessment is indicated in colorectal cancer, advanced non-small-cell lung cancer, melanoma, and thyroid cancer. BRAF StripAssay is an assay for the identification of BRAF p.V600E (c.1799T>A) based on polymerase chain reaction (PCR) and reverse-hybridization.
Thiopurine-based therapeutic drugs may accumulate to toxic levels in patients carrying genetic variants of the drug-metabolizing enzyme TPMT. The PGX-TPMT StripAssay® identifies the most frequent TPMT variants of therapeutic relevance. An assay for the identification of TPMT variants *2, *3A, *3B, and *3C associated with response to thiopurine therapy based on polymerase chain reaction (PCR) and reverse-hybridization.
© 2022 Goffin Molecular Technologies
After completion, Goffin Molecular Technologies will contact you as soon as possible.
You must be logged in to post a comment.